Heart failure (HF) is a complex syndrome with high morbidity and mortality while, myocardial
injury, hemodynamic overload, genetic, neurohormonal, inflammatory and biochemical …

Although substantial improvements have been made in majority of cardiac disorders, heart
failure (HF) remains a major health problem, with both increasing incidence and prevalence …

Biomarker testing in patients with heart failure (HF) is rapidly expanding. With high-quality
research indicating its diagnostic and prognostic capabilities, biomarkers are excellent …

Cardiovascular disease (CVD) is a serious public health concern whose incidence has been
on a rise and is projected by the World Health Organization to be the leading global cause of …

Heart failure (HF) is considered a leading cause of death in patients with established
cardiovascular (CV) and metabolic diseases. Although current treatment strategy has …

Heart failure (HF) may be considered as the fatal finishing line of all cardiovascular
disorders. There is not a single diagnostic test for HF, and its diagnosis relies on clinical …

The last decade has seen exciting advances in the field of biomarkers used in managing
patients with heart failure (HF). Biomarker research has broadened our knowledge base …

Early detection and risk stratification of patients with heart failure (HF) are crucial to improve
outcomes. Given the complexity of the pathophysiological processes of HF and the …

An always-rising prevalence of heart failure (HF), formerly classified as an emerging
epidemic in 1997 and still representing a serious problem of public health, imposes on us to …

There is a high prevalence of heart failure (HF) worldwide, which has significant
consequences for healthcare costs, patient death and quality of life. Therefore, there has …